Inhibitors of volatile sulfur compounds formation and screening methods therefor

Abstract

To provide methods for screening substances useful as an effective ingredient of a volatile deodorant that inhibits formation of volatile sulfur compounds.SOLUTION: A method for screening substances that inhibit formation of volatile sulfur compounds is provided. The screening method comprises: allowing for generation of volatile sulfur compounds from a formation source thereof by a catalytic reaction of a biocatalyst capable of generating volatile sulfur compounds in presence or absence of a test substance; and selecting a substance that inhibits the formation of volatile sulfur compounds by the biocatalyst using a difference in volatile sulfur compound formation amounts in the presence or absence of the test substance as an indicator, where the catalytic reaction in the presence of the test substance is carried out by introducing the vaporized test substance into a reaction system.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a method for screening for a substance that inhibits volatile sulfur compound-forming activity and a volatile sulfur compound formation inhibitor. [Background technology]

[0002] Volatile sulfur compounds are components contained in putrid odors that occur when food waste or the like decays. Volatile sulfur compounds are one of the unpleasant odor components in the home environment, where the putrid odor can be felt even at low concentrations, and there is a demand for an effective deodorizing or deodorizing technology for these compounds. In particular, since volatile sulfur compounds are relatively stable neutral compounds, it is difficult to deodorize them by chemical decomposition or adsorption, and there is a great demand for an effective deodorizing or deodorizing technology for them.

[0003] Food waste generates volatile sulfur compounds that cause putrid odors because they are decomposed by bacteria to produce volatile sulfur compounds such as methyl mercaptan and hydrogen sulfide, which are foul-smelling gases. For example, among volatile sulfur compounds, hydrogen sulfide is produced from the sulfur-containing amino acid cysteine ​​by the action of cysteine ​​desulfurase, and methyl mercaptan is produced from methionine by the action of methioninase (methionine-γ-lyase). In addition, the production of volatile sulfur compounds in the domestic environment may be caused by Pseudomonas aeruginosa, a type of aerobic gram-negative bacteria, or Escherichia coli, a type of facultative anaerobic gram-negative bacteria (see, for example, Patent Document 1).

[0004] Patent Document 1 reports that various fragrance ingredients have an inhibitory effect on the production of volatile sulfur compounds. Specifically, decanal, hexanal, octanal, benzaldehyde, citral, citronellal, hydroxycitronellal, β-ionone, methyl dihydrojasmonate, cis-jasmone, lyral, nootkatone, globanone, nerolidol, heliotropin, phenylpropylaldehyde, anisaldehyde, vanillin, cyclamen aldehyde, ethyl vanillin, helional, phenylacetaldehyde, cinnamic aldehyde, amylcinnamic aldehyde, hexylcinnamic aldehyde, methylnonylacetaldehyde, undecane, and the like. They have reported that aldehyde, undecanal, dodecanal, nonanal, dupical, tripral, myrac aldehyde, β-damascone, γ-methylionone, α-ionone, α-damascone, α-methylionone, 8-cyclohexadecen-1-one, 9-cycloheptadecen-1-one, 4-cyclopentadecene, 7-cyclohexadecenolide, 10-oxa-16-hexadecenolide, and phenylacetaldehyde dimethyl acetal inhibit the formation of volatile sulfur compounds from cysteine ​​and methionine. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2008-173441 A Summary of the Invention [Problem to be solved by the invention]

[0006] The invention disclosed in Patent Document 1 relates to a preparation that suppresses the generation of volatile sulfur compounds by topically applying it to a place in a domestic environment where volatile sulfur compounds, which have an unpleasant odor, are likely to be generated (e.g., paragraphs 0009, 0023, etc.). The preparations disclosed therein are specifically spray-type deodorants, dishwashing detergents, and fabric softeners (e.g., Examples 5 to 7 in paragraphs 0044 to 0049, etc.). In other words, the preparation disclosed in Patent Document 1 is envisioned as a drug that causes the above-mentioned fragrance to act in a liquid form on a system containing a source of volatile sulfur compounds (hereinafter referred to as a "liquid-phase reaction").

[0007] For this reason, in Patent Document 1, in a screening test of the above-mentioned fragrance ingredients used as active ingredients in a formulation, the ability of the above-mentioned fragrance ingredients to inhibit the formation of volatile sulfur compounds is evaluated by a liquid phase reaction. That is, in the screening test, a substrate solution containing methionine or cysteine, which are sources of volatile sulfur compounds, is contacted with a solution containing a microorganism or an enzyme derived from a microorganism that catalyzes the formation of volatile sulfur compounds and the above-mentioned fragrance as a test substance, and a reaction is allowed to occur, thereby evaluating the ability of the above-mentioned fragrance ingredients to inhibit the formation of volatile sulfur compounds (e.g., Examples 1 to 4 in paragraphs 0032 to 42, etc.).

[0008] Incidentally, there is a liquid deodorant that is stored in a container that is attached to the inside of the lid of, for example, a trash can with a lid, or that is hung. This type of liquid deodorant is volatile (volatile deodorant). The container that stores this volatile deodorant is provided with, for example, a microporous sheet in part that is permeable to gas but not to liquid, and the active ingredient vaporized from the liquid deodorant volatilizes to the outside of the container through the microporous sheet. In this case, the active ingredient vaporized to the outside of the container is introduced to and acts on a reaction system in which volatile sulfur compounds are produced from a source of volatile sulfur compounds in the gas phase (hereinafter referred to as a "gas phase reaction").

[0009] Through intensive research by the present inventors, it has been discovered that the mechanism of action of the above-mentioned active ingredient, i.e., a compound that inhibits the activity of a biocatalyst such as a microorganism or enzyme having volatile sulfur compound-producing activity (hereinafter also referred to as a "catalytic activity inhibitor"), on a biocatalyst differs depending on whether the catalytic activity inhibitor undergoes a liquid-phase or gas-phase reaction with a system containing a source of volatile sulfur compounds and the biocatalyst.

[0010] That is, a compound having excellent catalytic activity suppression ability in a liquid phase reaction may not be able to exhibit the same catalytic activity suppression ability in a gas phase reaction, and it was found that the above-mentioned screening test using a liquid phase reaction disclosed in Patent Document 1 does not allow for proper screening of catalytic activity suppressors that are expected to act on biocatalysts in a gas phase reaction. If this screening method is not appropriate, it becomes difficult to select a catalytic activity inhibitor to be used as an active ingredient in a volatile sulfur compound formation suppressor related to a volatile deodorant.

[0011] An object of the present invention is to provide a method for screening catalytic activity inhibitors that are useful as active ingredients in volatile sulfur compound formation inhibitors, which are volatile deodorants. [Means for solving the problem]

[0012] According to one aspect of the present invention, there is provided a method for screening for a substance that inhibits volatile sulfur compound production activity, comprising the steps of: Producing volatile sulfur compounds from a source of volatile sulfur compounds by a catalytic reaction of a biocatalyst having a volatile sulfur compound-producing activity in the presence or absence of a test substance; and Using the difference between the amount of volatile sulfur compounds produced in the presence of the test substance and the amount of volatile sulfur compounds produced in the absence of the test substance as an index, a substance that inhibits the volatile sulfur compound-producing activity of the biocatalyst is selected. Including, There is provided a screening method in which the catalytic reaction in the presence of the test substance is carried out by vaporizing the test substance and introducing the vapor phase into a reaction system.

[0013] According to another aspect of the present invention, there is provided a screening method according to the above aspect, which is used for screening for an active ingredient of an agent for suppressing the formation of volatile sulfur compounds.

[0014] According to yet another aspect of the present invention, there is provided the screening method according to the above aspect, wherein the volatile sulfur compound formation inhibitor is a volatile deodorant.

[0015] According to yet another aspect of the present invention, there is provided a screening method according to any one of the above aspects, wherein the biocatalyst comprises one or more selected from a microorganism or an enzyme.

[0016] According to yet another aspect of the present invention, there is provided a screening method according to any one of the above aspects, wherein the biocatalyst comprises one or more microorganisms selected from the genera Bacillus, Geotrichum and Galactomyces.

[0017] According to yet another aspect of the present invention, there is provided a screening method according to any of the above aspects, wherein the biocatalyst comprises one or more microorganisms selected from Bacillus cereus, Bacillus mycoides, Geotrichum cadidum and Galactomyces candidum.

[0018] According to yet another aspect of the present invention, there is provided the screening method according to any one of the above aspects, wherein the biocatalyst comprises one or more enzymes selected from methioninase and cysteine ​​desulfurase.

[0019] According to yet another aspect of the present invention, there is provided the screening method according to any of the above aspects, wherein the volatile sulfur compound is methyl mercaptan or hydrogen sulfide.

[0020] According to yet another aspect of the present invention, there is provided a screening method according to any of the above aspects, wherein the source of the volatile sulfur compound is methionine or cysteine.

[0021] According to yet another aspect of the present invention, there is provided a volatile sulfur compound production inhibitor containing as an active ingredient one or more of the above-mentioned substances that inhibit volatile sulfur compound production activity screened by the screening method of any of the above-mentioned aspects. Effect of the Invention

[0022] According to the present invention, it is possible to provide a method for screening catalytic activity inhibitors that are useful as active ingredients in volatile sulfur compound formation inhibitors, which are volatile deodorants. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Hereinafter, an embodiment of the present invention will be described. First Embodiment The screening method according to the first embodiment of the present invention is a method for screening for catalytic activity inhibitors that have the effect of inhibiting a biocatalyst having volatile sulfur compound-producing activity.

[0024] Here, "volatile sulfur compound generating activity" means activity to catalyze a reaction that generates volatile sulfur compounds using a source of volatile sulfur compounds as a substrate. Among volatile sulfur compounds, hydrogen sulfide is generated from the sulfur-containing amino acid cysteine ​​as a source by the action of a biocatalyst having volatile sulfur compound generating activity. Among volatile sulfur compounds, methyl mercaptan is generated from methionine as a source by the action of the biocatalyst. The catalytic activity inhibitor selected by the screening method according to this embodiment can be used as an active ingredient of a volatile sulfur compound generating inhibitor, and can be particularly suitably used as an active ingredient of a volatile type volatile sulfur compound generating inhibitor.

[0025] The screening method according to this embodiment includes the following steps: A step of generating volatile sulfur compounds from a source of volatile sulfur compounds by a catalytic reaction of a biocatalyst having a volatile sulfur compound generating activity in the presence or absence of a test substance; and and selecting a substance that inhibits the volatile sulfur compound-producing activity of the biocatalyst using the difference between the amount of the volatile sulfur compound produced in the presence of the test substance and the amount of the volatile sulfur compound produced in the absence of the test substance as an indicator.

[0026] The test substance screened by the screening method according to the present embodiment may be a fragrance or may not be a fragrance, and may be a synthetic substance or may be a natural substance. The test substance may be, for example, a natural or synthetic fragrance, a deodorant, an antibacterial agent, or an insecticide, and may be, for example, a terpene compound, an aliphatic ester compound, an aromatic ester compound, an aliphatic aldehyde compound, an aromatic aldehyde compound, an aliphatic alcohol compound, an aromatic alcohol compound, a ketone compound, an alicyclic compound, an aromatic compound, or a nitrogen-containing aliphatic compound. In one embodiment, the test substance is preferably a volatile substance. Here, the "volatile substance" refers to, for example, a component having a boiling point in the range of 50 to 400°C, which volatilizes at normal temperature and normal pressure (for example, 20°C and 1 atm) and becomes gaseous in the air.

[0027] The biocatalyst having volatile sulfur compound-generating activity can be appropriately selected from a living organism itself or a catalyst derived from a living organism and having volatile sulfur compound-generating activity. Examples of the living organism itself include microorganisms, etc. Examples of the catalyst derived from a living organism include enzymes, etc.

[0028] The microorganism may be, for example, a bacterium, yeast, or mold, and any microorganism known to have volatile sulfur compound-producing activity can be used. The present inventors have also confirmed that bacteria belonging to the genera Bacillus sp., Geoerichum sp., and Galactomyces sp. produce methyl mercaptan from methionine (Test Example 1). Specific examples of these bacteria include Bacillus cereus, Bacillus mycoides, Geoerichum candidum, and Galactomyces candidum.

[0029] As the enzyme, for example, an enzyme known to have volatile sulfur compound generating activity can be used, and specific examples thereof include methioninase, cysteine ​​desulfurase, and the like.

[0030] In the screening method according to the present embodiment, a volatile sulfur compound is generated from a source of a volatile sulfur compound by a catalytic reaction of a biocatalyst having a volatile sulfur compound generating activity. The catalytic reaction of the biocatalyst with the source is carried out, for example, by preparing a medium containing the biocatalyst and the source and leaving it to stand at a predetermined temperature for a predetermined time. The medium to be used is not particularly limited, and a medium suitable for the biocatalyst to be used can be appropriately selected from known media. The medium may be a liquid medium or a solid medium, for example, a standard agar medium can be used. The temperature required for the catalytic reaction may be, for example, within the range of 10 to 40°C. The time required for the catalytic reaction may be, for example, 1 to 72 hours. This catalytic reaction is carried out in the presence and absence of a test substance.

[0031] Here, the catalytic reaction in the presence of the test substance is carried out by vaporizing the test substance and introducing it in the gas phase into a reaction system of the biocatalyst and the generation source. Specifically, the gas phase test substance is brought into contact with a culture medium containing the biocatalyst and the generation source and allowed to stand at a predetermined temperature for a predetermined time (see Test Example 2).

[0032] In the screening method of this embodiment, a substance that inhibits the volatile sulfur compound production activity of a biocatalyst is selected using the difference between the amount of volatile sulfur compounds produced by the above catalytic reaction in the presence of the test substance and the amount of volatile sulfur compounds produced by the above catalytic reaction in the absence of the test substance as an indicator.

[0033] Here, the quantification of the difference in the amount of volatile sulfur compounds produced by the above catalytic reaction in the presence and absence of a test substance can be carried out, for example, using Ellman's reagent (5,5'-dithiobis(2-nitrobenzoic acid); DTNB). The case where the volatile sulfur compound is methyl mercaptan will be described as an example. The SH group contained in methyl mercaptan separates the SS bond contained in 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) in an amount equivalent to the amount of SH groups, producing 5-mercapto-2-nitrobenzoic acid (TNB). Methyl mercaptan can be quantified by measuring the absorbance (λmax=412 nm) of the SH group contained in TNB.

[0034] [ka]

[0035] The percentage calculated by the following formula (1) using the absorbance at 412 nm in the presence of the test substance and the absorbance at 412 nm in the absence of the test substance (blank) is the inhibition rate of volatile sulfur compound production, and catalytic activity inhibitors can be screened from the test substances using this as a standard. In the screening method according to this embodiment, test substances with this inhibition rate of, for example, 50% or more are selected as catalytic activity inhibitors that inhibit the volatile sulfur compound production activity of the biocatalyst.

[0036]

number

[0037] <Second embodiment> The volatile sulfur compound formation inhibitor according to the second embodiment of the present invention contains a substance screened by the screening method according to the first embodiment, i.e., a catalytic activity inhibitor, as an active ingredient. The catalytic activity inhibitor screened by the screening method according to the first embodiment exhibits a catalytic activity inhibitory effect particularly effectively in a gas-phase reaction in which the inhibitor comes into contact with a biocatalyst in the gas phase. For this reason, the volatile sulfur compound formation inhibitor according to the second embodiment is preferably a volatile deodorant.

[0038] In one embodiment, the volatile sulfur compound formation inhibitor of this embodiment contains, as an active ingredient (catalytic activity inhibitor), one or more of the compounds shown below that have been screened by the screening method of the first embodiment.

[0039] That is, the volatile sulfur compound generation inhibitor of this embodiment contains, as an active ingredient, at least one compound selected from monoterpenes (excluding those containing an aldehyde group), aliphatic ester compounds represented by formula I, aromatic ester compounds represented by formula IIa or formula IIb, aliphatic aldehyde compounds represented by formula III, aromatic aldehyde compounds represented by formula IV, aliphatic alcohol compounds represented by formula V, aromatic alcohol compounds represented by formula VI, ketone compounds represented by formula VII, alicyclic compounds represented by formula VIII, aromatic compounds represented by formula IX, and nitrogen-containing aliphatic compounds. These compounds will be described below.

[0040] <Monoterpene> The monoterpene may be an acyclic monoterpene, a monocyclic monoterpene, or a bicyclic monoterpene, except for those containing an aldehyde group. The monoterpene preferably contains at least one selected from the group consisting of a hydroxyl group, an ester bond, a carbonyl group, a cycloalkenyl group, and an ether bond. Preferred specific examples of monoterpenes include the compounds shown in Table 1.

[0041] [Table 1]

[0042] <Aliphatic ester compounds> The aliphatic ester compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula I.

[0043] [ka]

[0044] In formula I, R 11 represents an alkyl group having 1 to 5 carbon atoms, a cyclic saturated aliphatic group, or an unsaturated aliphatic group; R 12 represents a saturated aliphatic group or an unsaturated aliphatic group, L 11 represents a single bond, an ether bond or an ester bond; L 12 represents a single bond or an alkylene group; L 13 represents a single bond or a divalent linking group. 11 -L 11 -L 12 - is CH 13 -Unless otherwise stated.

[0045] R 11 The alkyl group having 1 to 5 carbon atoms, represented by the formula (I) may be linear or branched, and examples thereof include a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, a tert-butyl group, and an n-pentyl group.

[0046] R 11 The cyclic saturated aliphatic group represented by may be monocyclic or polycyclic. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. R11 may be a combination of the above-mentioned alkyl group and a cyclic saturated aliphatic group.

[0047] R 11 Specific examples of the unsaturated aliphatic group represented by the formula include an alkenyl group, an alkynyl group, and a monocyclic or polycyclic unsaturated aliphatic group. The alkenyl group may be linear or branched, and the number of carbon atoms is, for example, 2 to 12, or 5 to 10. The alkynyl group may be linear or branched, and the number of carbon atoms is, for example, 2 to 12, or 5 to 10. Examples of the monocyclic unsaturated aliphatic group include a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, a cyclononenyl group, and a cyclodecenyl group. Examples of the polycyclic unsaturated aliphatic group include an adamantenyl group, a norbornenyl group, an isobornenyl group, a tricyclodecenyl group, and a tetracyclododecenyl group. R 11 may be a combination of two or more of the above mentioned unsaturated aliphatic groups.

[0048] R 12 Specific examples of the saturated aliphatic group represented by the formula include an alkyl group and a monocyclic or polycyclic saturated aliphatic group. The alkyl group may be linear or branched, and has, for example, 1 to 12 carbon atoms, or 5 to 10 carbon atoms. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. R 12 The saturated aliphatic group represented by the formula may be a combination of two or more of these.

[0049] R 12 Specific examples of the unsaturated aliphatic group represented by the formula 11 The above-mentioned unsaturated aliphatic groups are similar to those represented by the following formula:

[0050] L 12 The alkylene group represented by the formula: may be linear or branched and has, for example, 1 to 7 carbon atoms, or 1 to 5 carbon atoms.

[0051] L 13 Specific examples of the divalent linking group represented by the formula (I) include an alkylene group, an ether bond, a carbonyl group, or an alkylene group, or a combination of two or more selected from an alkylene group, an ether bond, and a carbonyl group. Here, the alkylene group may be linear or branched, and may contain a ring structure.

[0052] Preferred specific examples of the aliphatic ester compound represented by formula I include the compounds shown in Table 2.

[0053] [Table 2-1] [Table 2-2]

[0054] <Aromatic ester compounds> The aromatic ester compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula IIa or formula IIb.

[0055] [ka]

[0056] In formula IIa, R 21 represents a hydrogen atom or a substituent, R 22 represents a saturated aliphatic group, an unsaturated aliphatic group, or a phenyl group; L 21 and L 22 each independently represents a single bond or a divalent linking group.

[0057] R 21Examples of the substituent represented by the formula include a hydroxyl group or an amino group.

[0058] R 22 Specific examples of the saturated aliphatic group represented by the formula include an alkyl group and a monocyclic or polycyclic saturated aliphatic group. The alkyl group may be linear or branched, and has, for example, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. R 22 The saturated aliphatic group represented by the formula may be a combination of two or more of these.

[0059] R 22 Specific examples of the unsaturated aliphatic group represented by the formula include an alkenyl group, an alkynyl group, and a monocyclic or polycyclic unsaturated aliphatic group. The alkenyl group may be linear or branched, and the number of carbon atoms is, for example, 2 to 10, or 3 to 6. Examples of the monocyclic unsaturated aliphatic group include a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, a cyclononenyl group, and a cyclodecenyl group. Examples of the polycyclic unsaturated aliphatic group include an adamantenyl group, a norbornenyl group, an isobornenyl group, a tricyclodecenyl group, and a tetracyclododecenyl group. R 22 The unsaturated aliphatic group represented by the formula may be a combination of two or more of the above unsaturated aliphatic groups, or may be a combination of the above saturated aliphatic group and the above unsaturated aliphatic group.

[0060] L 21 Specific examples of the divalent linking group represented by the formula (I) include an alkylene group. 21The alkylene group as L may be linear or branched, may contain a ring structure, or may contain a heteroatom such as an oxygen atom. For example, L 21 The divalent linking group as may contain an epoxy structure.

[0061] L 22 Specific examples of the divalent linking group represented by the formula (I) include an ether bond or an alkylene group, or a combination of an ether bond and an alkylene group. The alkylene group may be linear or branched, and may contain a ring structure.

[0062] In formula IIb, R 23 represents a saturated aliphatic group, and L 23 represents a single bond or a divalent linking group; L 24 represents a divalent linking group.

[0063] R 23 Specific examples of the saturated aliphatic group represented by the formula include an alkyl group and a monocyclic or polycyclic saturated aliphatic group. The alkyl group may be linear or branched, and has, for example, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. R 23 The saturated aliphatic group represented by the formula may be a combination of two or more of these.

[0064] L 23 Specific examples of the divalent linking group represented by the formula include an alkylene group. The alkylene group may be linear or branched, and may contain a ring structure. L 24 Specific examples of the divalent linking group represented by the formula include an alkylene group. The alkylene group may be linear or branched, and may contain a ring structure.

[0065] Preferred specific examples of the aromatic ester compound represented by formula IIa or IIb include the compounds shown in Table 3.

[0066] [Table 3]

[0067] <Aliphatic aldehyde compounds> The aliphatic aldehyde compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula III.

[0068] [ka]

[0069] In formula III, R3 represents a saturated aliphatic group, a linear unsaturated aliphatic group having from 2 to 8 carbon atoms, a cyclic unsaturated aliphatic group, or an alkenyloxy group.

[0070] Specific examples of the saturated aliphatic group represented by R3 include an alkyl group and a monocyclic or polycyclic saturated aliphatic group. The alkyl group may be linear or branched, and may have, for example, 1 to 15 carbon atoms, or 6 to 12 carbon atoms. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. The saturated aliphatic group represented by R3 may be a combination of two or more of these.

[0071] Specific examples of the chain unsaturated aliphatic group having 2 to 8 carbon atoms represented by R3 include linear or branched alkenyl groups having 2 to 8 carbon atoms, and linear or branched alkynyl groups having 2 to 8 carbon atoms.

[0072] Specific examples of the cyclic unsaturated aliphatic group represented by R3 include monocyclic or polycyclic unsaturated aliphatic groups. Examples of the monocyclic unsaturated aliphatic groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl groups. Examples of the polycyclic unsaturated aliphatic groups include adamantenyl, norbornenyl, isobornenyl, tricyclodecenyl, and tetracyclododecenyl groups. R3 may be a combination of two or more groups selected from the chain and cyclic unsaturated aliphatic groups listed above.

[0073] The alkenyl group contained in the alkenyloxy group may be linear or branched. The number of carbon atoms contained in this alkenyl group is, for example, 2 to 12, or 5 to 10.

[0074] Preferred specific examples of the aliphatic aldehyde compound represented by formula III include the compounds shown in Table 4.

[0075] [Table 4]

[0076] <Aromatic aldehyde compounds> The aromatic aldehyde compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula IV.

[0077] [ka]

[0078] In formula IV, L4 represents a divalent linking group, and R4 represents a hydrogen atom or a substituent. Specific examples of the divalent linking group represented by L4 include an alkylene group. The alkylene group may be linear or branched, and may contain a ring structure.

[0079] Specific examples of the substituent represented by R4 include an alkyl group and an alkenyl group.

[0080] Preferred specific examples of the aromatic aldehyde compound represented by formula IV include the compounds shown in Table 5.

[0081] [Table 5]

[0082] <Fatty alcohol compounds> The aliphatic alcohol compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula V. [ka]

[0083] In formula V, R5 represents a saturated aliphatic group, a chain unsaturated aliphatic group having from 2 to 14 carbon atoms, or a cyclic unsaturated aliphatic group.

[0084] Specific examples of the saturated aliphatic group represented by R5 include an alkyl group and a monocyclic or polycyclic saturated aliphatic group. The alkyl group may be linear or branched, and may have, for example, 1 to 15 carbon atoms, or 5 to 12 carbon atoms. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. The saturated aliphatic group represented by R5 may be a combination of two or more of these.

[0085] The chain unsaturated aliphatic group having 2 to 14 carbon atoms represented by R5 includes an alkenyl group or an alkynyl group. The alkenyl group may be linear or branched and has 2 to 14 carbon atoms, or has 6 to 12 carbon atoms. The alkynyl group may be linear or branched and has 2 to 14 carbon atoms, or has 6 to 12 carbon atoms.

[0086] The cyclic unsaturated aliphatic group represented by R5 may be monocyclic or polycyclic. Examples of monocyclic unsaturated aliphatic groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl. Examples of polycyclic unsaturated aliphatic groups include adamantenyl, norbornenyl, isobornenyl, tricyclodecenyl, and tetracyclododecenyl.

[0087] R5 may be a combination of the above-listed linear unsaturated aliphatic groups and cyclic unsaturated aliphatic groups, or a combination of the above-listed saturated aliphatic groups and dry unsaturated aliphatic groups.

[0088] Preferred specific examples of the aliphatic alcohol compound represented by formula V include the compounds shown in Table 6.

[0089] [Table 6]

[0090] <Aromatic alcohol compounds> The aromatic alcohol compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula VI. [ka]

[0091] In formula VI, R6 represents a divalent linking group. Specific examples of the divalent linking group represented by R6 include an alkylene group or an alkenylene group. The alkylene group and the alkenylene group may be linear or branched, and may contain a ring structure.

[0092] Preferred specific examples of the aromatic alcohol compound represented by formula VI include the compounds shown in Table 7.

[0093] [Table 7]

[0094] <Ketone compounds> The ketone compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula VII. [ka]

[0095] In formula VII, R 71 represents a saturated aliphatic group or an unsaturated aliphatic group, R 72 represents an unsaturated aliphatic group or a phenyl group.

[0096] R 71 Specific examples of the saturated aliphatic group represented by the formula include an alkyl group and a monocyclic or polycyclic saturated aliphatic group. The alkyl group may be linear or branched, and has, for example, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. R 71 The saturated aliphatic group represented by the formula may be a combination of two or more of these.

[0097] R 71 and R72 Specific examples of the unsaturated aliphatic group represented by the formula include an alkenyl group, an alkynyl group, and a monocyclic or polycyclic unsaturated aliphatic group. The alkenyl group may be linear or branched, and the number of carbon atoms is, for example, 2 to 10, or 3 to 6. The alkynyl group may be linear or branched, and the number of carbon atoms is, for example, 2 to 10, or 3 to 6. Examples of the monocyclic unsaturated aliphatic group include a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, a cyclononenyl group, and a cyclodecenyl group. Examples of the polycyclic unsaturated aliphatic group include an adamantenyl group, a norbornenyl group, an isobornenyl group, a tricyclodecenyl group, and a tetracyclododecenyl group. R 71 and R 72 The unsaturated aliphatic group represented by the formula may be a combination of two or more of the above unsaturated aliphatic groups, or may be a combination of the above saturated aliphatic group and the above unsaturated aliphatic group.

[0098] Preferred specific examples of the ketone compound represented by formula VII include the compounds shown in Table 8.

[0099] [Table 8]

[0100] <Alicyclic compounds> The alicyclic compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula VIII. [ka]

[0101] In formula VIII, Z represents a monocyclic or polycyclic alicyclic ring containing at least one ring member selected from an ether bond, an ester bond, and a carbonyl group, R8 represents a substituent selected from an alkyl group, an alkenyl group, a hydroxyl group, a phenyl group, -L8-C(=O)H (wherein L8 represents an alkylene group), and -C(=O)OCH3, and n8 represents an integer of 0 to 6. When n8 is 2 or more, multiple R8s may be the same or different.

[0102] Z is a monocyclic or polycyclic alicyclic ring containing at least one selected from an ether bond, an ester bond, and a carbonyl group as a ring member. When Z is a polycyclic ring, Z may be a ring structure in which an alicyclic ring and an aromatic ring are combined. The number of carbon atoms constituting the alicyclic ring as Z is, for example, 4 to 20, or 4 to 15.

[0103] The alkyl group represented by R8 may be linear or branched, and the number of carbon atoms is, for example, from 1 to 10, or from 3 to 6. The alkenyl group represented by R8 may be linear or branched, and the number of carbon atoms is, for example, from 2 to 10, or from 3 to 6. In -L8-C(=O)H represented by R8, the alkylene group as L8 may be linear or branched, and may contain a ring structure.

[0104] Preferred specific examples of the alicyclic compound represented by formula VIII include the compounds shown in Table 9.

[0105] [Table 9]

[0106] <Aromatic compounds> The aromatic compound contained in the volatile sulfur compound formation inhibitor according to the present invention is a compound represented by formula IX. [ka]

[0107] In formula IX, R 91 R represents a hydrogen atom, a saturated aliphatic group, or an unsaturated aliphatic group. 91 is a saturated aliphatic group or an unsaturated aliphatic group, R 92 represents a hydroxyl group or an alkoxyl group, R 91 is a hydrogen atom, R 92 R represents a phenoxy group. 93 represents a hydrogen atom or a substituent.

[0108] R 91 Specific examples of the saturated aliphatic group represented by the formula include an alkyl group and a monocyclic or polycyclic saturated aliphatic group. The alkyl group may be linear or branched, and has, for example, 1 to 5 carbon atoms, or 1 to 3 carbon atoms. Examples of the monocyclic saturated aliphatic group include a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclononyl group, and a cyclodecyl group. Examples of the polycyclic aliphatic hydrocarbon group include an adamantyl group, a norbornyl group, an isobornyl group, a tricyclodecanyl group, and a tetracyclododecanyl group. R 91 The saturated aliphatic group represented by the formula may be a combination of two or more of these.

[0109] R 91 Specific examples of the unsaturated aliphatic group represented by the formula include an alkenyl group, an alkynyl group, or a monocyclic or polycyclic unsaturated aliphatic group. The alkenyl group may be linear or branched, and the number of carbon atoms is, for example, 2 to 5, or 3 to 5. The alkynyl group may be linear or branched, and the number of carbon atoms is, for example, 2 to 5, or 3 to 5. Examples of the monocyclic unsaturated aliphatic group include a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a cyclooctenyl group, a cyclononenyl group, and a cyclodecenyl group. Examples of the polycyclic unsaturated aliphatic group include an adamantenyl group, a norbornenyl group, an isobornenyl group, a tricyclodecenyl group, and a tetracyclododecenyl group. R91 The unsaturated aliphatic group represented by the formula may be a combination of two or more of the above unsaturated aliphatic groups, or may be a combination of the above saturated aliphatic group and an unsaturated aliphatic group.

[0110] R 92 The alkyl group contained in the alkoxyl group represented by the formula (I) may be linear or branched, and has, for example, 1 or more and 5 or less, or 1 or more and 3 or less, carbon atoms.

[0111] R 93 Examples of the substituent represented by the formula (R) include an alkyl group and an alkoxy group. 93 The alkyl group as R may be linear or branched and may have, for example, 1 to 5 carbon atoms, or 1 to 3 carbon atoms. 93 The alkyl group contained in the alkoxyl group as may be linear or branched and has, for example, 1 or more and 5 or less, or 1 or more and 3 or less, carbon atoms.

[0112] Preferred specific examples of the aromatic compound represented by formula IX include the compounds shown in Table 10.

[0113] [Table 10]

[0114] <Nitrogen-containing aliphatic compounds> The volatile sulfur compound formation inhibitor according to the present invention may contain a nitrogen-containing aliphatic compound. Preferred nitrogen-containing aliphatic compounds include, for example, the compounds shown in Table 11.

[0115] [Table 11]

[0116] The above-mentioned compounds that can be contained as an active ingredient in the volatile sulfur compound generation inhibitor of the present invention are volatile compounds that have been conventionally known as fragrance ingredients. These compounds may be, for example, those isolated from natural products or those chemically synthesized. They may also be used as essential oils such as lemongrass oil, verbena oil, lemon myrtle oil, lemon oil, orange oil, thyme oil, clove oil, pimento oil, bay leaf oil, cinnamon oil, and ylang-ylang oil, which contain the above-mentioned compounds.

[0117] The volatile sulfur compound production inhibitor of the present invention can use one or more of the above compounds. The above compounds are not limited in their form of use as long as they suppress the production of volatile sulfur compounds by gas-phase reaction with bacteria or enzymes that contribute to the production of volatile sulfur compounds such as methyl mercaptan. The volatile sulfur compound production inhibitor of the present invention may be an agent consisting of only one or more of the above compounds, or may contain other components in addition to the above compounds as necessary. Examples of other components include solvents, surfactants, deodorants, insect repellents, repellents, antibacterial agents, fungicides, dyes, pigments, antioxidants, ultraviolet absorbers, and fragrance components.

[0118] The volatile sulfur compound generation inhibitor of the present invention can be formulated into various dosage forms by a conventionally known method by blending the above-mentioned compound with optional components as necessary. Specific examples of the dosage form include liquid, gel, sheet, solid, etc. Among these dosage forms, the volatile sulfur compound generation inhibitor of the present invention is preferably in liquid form.

[0119] When a support is used to support the volatile sulfur compound formation inhibitor of the present invention, examples of the support include wood, paper, cloth, nonwoven fabric, silica, talc, activated carbon, silica gel, zeolite, fluorite, cellulose beads, activated carbon, ceramics, etc.

[0120] When the volatile sulfur compound generation inhibitor of the present invention is gelled using a gelling agent, a conventionally known gelling agent can be used, such as carrageenan, gellan gum, agar, gelatin, guar gum, pectin, locust bean gum, xanthan gum, sodium alginate, cellulose derivatives, highly water-absorbent resins such as sodium acrylate, dibenzylidene-D-sorbitol, and hydroxypropylated polysaccharides.

[0121] The volatile sulfur compound formation inhibitor of the present invention can be used for, for example, food waste as a source of volatile sulfur compounds. By placing the volatile sulfur compound formation inhibitor of the present invention in garbage bins and triangular corners installed in general homes, restaurants, campsites, barbecue sites, etc. where food waste is generated, the generation of methyl mercaptan, which is a putrid odor generated from food waste, can be effectively suppressed.

[0122] Examples of the method of applying the volatile sulfur compound generation inhibitor of the present invention include a method of placing a volatile sulfur compound generation inhibitor in a liquid, gel, sheet, solid, or other form near a source of volatile sulfur compounds such as food waste and allowing it to volatilize naturally at room temperature, and a method of directly spraying a liquid volatile sulfur compound generation inhibitor on a source of volatile sulfur compounds. As described above, the above-mentioned compound contained as an active ingredient in the volatile sulfur compound generation inhibitor of the present invention reacts with bacteria or enzymes in a vaporized state, thereby particularly effectively suppressing the generation of methyl mercaptan from methionine. Therefore, a preferred method of applying the volatile sulfur compound generation inhibitor of the present invention is to place the inhibitor in a closed space containing food waste, such as a trash can with a lid, and allow it to volatilize naturally at room temperature. The amount of the compound of the present invention that volatilizes in a closed space by such a method is, for example, preferably such that the concentration of the compound of the present invention in the space is 0.01% by mass or more.

[0123] The volatile sulfur compound formation inhibitor of the present invention is preferably allowed to volatilize naturally at room temperature, particularly using a chemical volatilizer that contains the volatile sulfur compound formation inhibitor.

[0124] Such a chemical volatilizer is not particularly limited, but for example, as a first embodiment, a chemical volatilizer in which a liquid volatile sulfur compound generation inhibitor of the present invention is contained in a container at least partly made of a microporous sheet can be mentioned. The chemical volatilizer according to the first embodiment can be, for example, a bag-shaped container whose entire container is made of a microporous sheet, and a liquid volatile sulfur compound generation inhibitor is contained in this bag-shaped container. Alternatively, the chemical volatilizer according to the first embodiment can be a container whose upper surface is open, in which a liquid volatile sulfur compound generation inhibitor of the present invention is contained, and the opening is blocked with a microporous sheet.

[0125] The microporous sheet provided in the medicine volatilizer according to the first embodiment is a sheet having fine holes that are permeable to gas but not to liquid. Examples of the microporous sheet include a sheet with a filler added, a sheet made of a physically foamed resin film, and a sheet made of a resin with a foaming agent added. The diameter of the holes in the microporous sheet is not particularly limited, but is usually preferably about 0.1 to 10 μm from the viewpoints of suppressing leakage of medicine and efficiently volatilizing the medicine. These sheets may be a single film or a composite film made by bonding two or more films.

[0126] The material of the microporous sheet is not particularly limited, and examples thereof include thermoplastic resins such as polyolefin resins and those treated with fluorine or silicone to make them water repellent. The microporous sheet is preferably a drug-permeable sheet obtained by stretching a resin composition in which a filler is blended with a polyolefin resin, to give fine pores. In the drug volatilizer according to the first embodiment, the volatile sulfur compound generation inhibitor of the present invention volatilizes through the microporous sheet and reacts and acts on bacteria and enzymes in a gaseous state.

[0127] In addition, the chemical volatilizer according to the second embodiment may be a container equipped with a volatilization port and capable of being opened and closed, in which a chemical impregnated body impregnated with the volatile sulfur compound generation inhibitor of the present invention is housed. As the chemical impregnated body, filter paper, pulp impregnated paper, etc. can be used. In the chemical volatilizer according to the second embodiment, the volatile sulfur compound generation inhibitor of the present invention volatilizes from the volatilization port and reacts and acts on bacteria and enzymes in a gaseous state.

[0128] The drug volatilizer may be provided with a member for hanging the drug volatilizer or a member for attaching the drug volatilizer. This allows the drug volatilizer to be attached or hung, for example, on the back surface of a trash can lid. For the drug volatilizer according to the first and second embodiments described here, for example, refer to Figures 1 to 4 in Japanese Patent No. 5871746. EXAMPLES

[0129] Test examples carried out in relation to the present invention are described below. (Test Example 1) Identification of methyl mercaptan-producing bacteria A simulated food waste was prepared according to Table 12. After leaving it at 25°C for one week, 40 g of the simulated food waste was suspended in 30 ml of physiological saline and shaken for 30 minutes to obtain a liquid, which was used as a food waste extract. The extracted food waste extract was spread on a standard agar medium and isolated and cultured to obtain six types of isolated bacteria (test bacteria 1 to 6) described below. Test bacteria 1 to 6 were evaluated for their ability to produce methyl mercaptan from methionine by the following method.

[0130] [Table 12]

[0131] One colony was taken from each of the test bacteria 1 to 6 and cultured in normal bouillon medium for 24 hours to prepare a culture solution for each of the test bacteria 1 to 6.

[0132] The food waste extract or each culture solution prepared above was placed in a standard agar medium containing methionine in a 10L plastic bag, filled with odorless air, and left to stand. The initial concentration of the malodorous component (methyl mercaptan) in the plastic bag at room temperature (25°C) and the concentration of the malodorous component (methyl mercaptan) after a certain period of time (24 hours, 48 ​​hours) were measured using a detector tube (Gastec Corporation, methyl mercaptan detector tube No. 71). The measurement results are shown in Table 13.

[0133] "Blank" in Table 13 refers to the measurement results of the concentration of the malodorous component (methyl mercaptan) when normal bouillon medium was added instead of the culture medium and a standard agar medium containing methionine was used.

[0134] [Table 13]

[0135] The test specimens 2, 3 and 6, which were confirmed to produce methyl mercaptan in Table 13, were shown to be highly likely to be the following species as a result of homology analysis using the 16S rRNA base sequence. Test bacterium 2: Bacillus cereus Test bacterium 3: Bacillus mycoides Test bacteria 6 Geoerichum candidum, Galactomyces candidum

[0136] As shown in Table 13, production of methyl mercaptan was confirmed when the target bacteria 2 (Bacillus cereus), 3 (Bacillus mycoides), and 6 (Geotrichum candidum, Galactomyces candidum) were used among the target bacteria 1 to 6. It was found that these microorganisms have the ability to generate methyl mercaptan from methionine.

[0137] Furthermore, from the measurement results in Table 13, it can be seen that among these specimens 2, 3, and 6, Bacillus cereus in specimen 2 has the same methyl mercaptan production behavior as the food waste extract. Moreover, specimens 2 and 6 are known to be microorganisms detected in food. Based on these results, it was decided to use this Bacillus cereus as the bacterial cell in the screening test of the compounds described below. By using Bacillus cereus as the bacterial cell, which shows the same methyl mercaptan production behavior as the food waste culture solution isolated from the simulated food waste, it is possible to find an agent that is particularly effective in suppressing the odor generated from food waste by screening.

[0138] (Test Example 2) Evaluation of the ability to inhibit the catalytic activity of a biocatalyst capable of producing volatile sulfur compounds A centrifugal ultrafiltration filter unit (Amicon (registered trademark) Ultra-15 (Merck)) consisting of a lower container (centrifugation test tube) and an upper container (filter cup) was prepared. A suspension of 25 μl of the culture solution of Bacillus cereus prepared in Test Example 1 and 25 μl of 200 mM methionine aqueous solution was added to 0.5 g of standard agar medium in the lower container to prepare a lower layer.

[0139] Filter paper was impregnated with 10 μl of each of the compounds shown in Tables 14 and 15 below, which were screening targets (test substances). The filter paper impregnated with each compound was attached to the bottom surface of the upper container of the filter unit. This upper container was attached to the lower container equipped with the lower layer shown above.

[0140] Next, 1 ml of 2 mM 5,5'-dithiobis(2-nitrobenzoic acid) diluted with 0.25 M phosphate buffer (pH 7.2) was added to the upper container, and this was used as the upper layer. The obtained sample was left to stand at 25°C for 24 hours. A blank was prepared by replacing the filter paper with one not impregnated with the compound.

[0141] After 24 hours, 1 mL of the solution from the upper layer of each sample was measured for absorbance at 412 nm using a V-650 spectrophotometer. From the measured values, the inhibition rate (%) of the formation of volatile sulfur compounds was calculated according to the following formula (1). The results are shown in Tables 14 and 15. In addition, a negative value in the inhibition rate shown in Table 15 means that the production of methyl mercaptan is promoted compared to the blank.

[0142]

number

[0143] [Table 14-1]

[0144] [Table 14-2]

[0145] [Table 14-3]

[0146] [Table 14-4]

[0147] [Table 14-5]

[0148] [Table 14-6]

[0149] [Table 14-7]

[0150] [Table 14-8]

[0151] [Table 15]

[0152] The present invention is not limited to the above-mentioned embodiment, and can be modified in various ways without departing from the gist of the present invention. The embodiments may be combined as appropriate, and in that case, the combined effect can be obtained. Furthermore, the above-mentioned embodiment includes various inventions, and various inventions can be extracted by combinations selected from the multiple components disclosed. For example, if the problem can be solved and the effect can be obtained even if some components are deleted from all the components shown in the embodiment, the configuration from which the components are deleted can be extracted as an invention.

Claims

1. A method for screening for a substance that inhibits volatile sulfur compound production activity, comprising the steps of: Producing volatile sulfur compounds from a source of volatile sulfur compounds by a catalytic reaction of a biocatalyst having a volatile sulfur compound-producing activity in the presence or absence of a test substance; and and selecting a substance that inhibits the volatile sulfur compound-producing activity of the biocatalyst using the difference between the amount of the volatile sulfur compound produced in the presence of the test substance and the amount of the volatile sulfur compound produced in the absence of the test substance as an index. Including, A screening method in which the catalytic reaction in the presence of the test substance is carried out by vaporizing the test substance and introducing the vapor phase into a reaction system.

2. 2. The screening method according to claim 1, which is used for screening an active ingredient of an inhibitor of the formation of volatile sulfur compounds.

3. The screening method according to claim 2, wherein the volatile sulfur compound formation inhibitor is a volatile deodorant.

4. The screening method according to claim 1 , wherein the biocatalyst comprises one or more selected from a microorganism and an enzyme.

5. The screening method according to claim 1 , wherein the biocatalyst comprises one or more microorganisms selected from the genera Bacillus, Geotrichum and Galactomyces.

6. The method of claim 1, wherein the biocatalyst comprises one or more microorganisms selected from the group consisting of Bacillus cereus, Bacillus mycoides, Geotrichum cadidum, and Galactomyces candidum.

7. The screening method according to claim 1 , wherein the biocatalyst comprises one or more enzymes selected from methioninase and cysteine ​​desulfurase.

8. The screening method according to claim 1, wherein the volatile sulfur compound is methyl mercaptan or hydrogen sulfide.

9. The screening method according to claim 1 , wherein the source of the volatile sulfur compound is methionine or cysteine.

10. A volatile sulfur compound production inhibitor comprising, as an active ingredient, one or more of the substances that inhibit volatile sulfur compound production activity screened by the screening method described in any one of claims 1 to 9.

Images